Mei Hsuan Tsai
About Mei Hsuan Tsai
Mei Hsuan Tsai is a Senior Principal Investigator at BeiGene in Pudong, Shanghai, China, specializing in Antibody-Drug-Conjugates (ADC) Discovery and Development.
Company
Mei Hsuan Tsai is currently employed at BeiGene, located in Pudong, Shanghai, China. BeiGene is a biotechnology company that specializes in the development of molecularly targeted and immuno-oncology drug candidates.
Title
Mei Hsuan Tsai holds the position of Senior Principal Investigator at BeiGene, having started this role in July 2020. In this capacity, Tsai focuses on leading high-level research projects and contributing to the advancement of drug discovery and development.
Education and Expertise
Mei Hsuan Tsai studied at the University of Cambridge, UK, earning a Ph.D. in Synthetic Organic Chemistry. This followed a Master’s Degree in the same field from the University of York, UK, and a Bachelor’s Degree in Chemistry from National Chung Hsing University, Taiwan. Tsai specializes in Antibody-Drug-Conjugates (ADC) Discovery and Development.
Professional Background
Before joining BeiGene, Mei Hsuan Tsai served as an Associate Director at HitGen Inc. overseeing the Discovery Chemistry Unit from 2018 to 2020. Prior to that, Tsai worked at WuXi Biologics as an Associate Director for 4 months in 2017-2018, and as a Principal Scientist I, Project Leader, from 2015 to 2017. Tsai's early career includes a role at the Industrial Technology Research Institute (ITRI) in Taiwan, where Tsai worked as a PhD Researcher in the Medicinal Chemistry Division from 2013 to 2015.